Aug 2026· Cell Cycle· Vol 25 1, pp.
1-14
· 0 citations· 35 references
Medicine
TL;DR
It is found that p53 upregulates ITM2A expression, while ITM2A in turn inhibits p53 function, suggesting a negative feedback loop and suggesting ITM2A as a potential prognostic marker and therapeutic target for cancers with dysregulated p53 signaling.
Abstract
The tumor suppressor p53 plays a crucial role in preventing cancer development, and its dysfunction is frequently observed in various cancers. This study identifies a novel regulatory interaction between p53 and ITM2A. We found that p53 upregulates ITM2A expression, while ITM2A in turn inhibits p53 function, suggesting a negative feedback loop. ITM2A mRNA levels were reduced across multiple tumor types, particularly in those harboring mutant p53, and low ITM2A expression correlated with poor patient survival. Mechanistically, ITM2A physically interacts with p53, selectively modulates its phosphorylation (reducing Ser392 while enhancing Ser37), and promotes cytoplasmic accumulation of p53. These modifications collectively suppress p53-dependent transcription, an effect consistently observed across multiple cell lines under both basal conditions and upon physiological p53 activation by genotoxic stress. Conversely, ITM2A depletion enhances p53 nuclear accumulation and transcriptional activity. These findings reveal a novel autoregulatory circuit wherein p53 induces ITM2A expression, which then attenuates p53 activity, suggesting ITM2A as a potential prognostic marker and therapeutic target for cancers with dysregulated p53 signaling.
Results suggest that MDM2 3’UTR elongation may trigger a non-canonical regulatory mechanism that bypasses the traditional MDM2-p53 interaction, and suggests that APA-mediated gene modulation can induce unforeseen compensatory survival pathways in cancer cells, necessitating further investigation into the broader functi...
Minseo Kim, Celine Yoon, Jaewan Jun et al.· bioRxiv· 0 citations
The MDM2/p53/p14ARF axis represents a central regulatory network controlling cell-cycle progression, genomic stability, and tumor suppression, and is frequently deregulated in human cancers. In many malignancies, particularly those retaining wild-type TP53, p53 activity is functionally suppressed through MDM2 overexpre...
S. B. de Oliveira, A. L. V. Alves, Bianca Naomi Niitsuma et al.· Molecular and Cellular Bioch...· 0 citations
Highlights What are the main findings? Chemotherapeutic agents targeting p53 downregulate ATF4 mRNA in a stress-dependent manner. p21 and p130 contribute to the specific p53-dependent downregulation of ATF4 mRNA upon mitochondrial dysfunction. ATF4 mRNA levels are reduced under hypoxic conditions and partially restored...
Alexandra A. Dalina, Maria Shilyaeva, I. Kovaleva et al.· Cells· 0 citations
Cancer stem-like cells (CSCs) are believed to be a pivotal contributor to therapy failure in various cancers including osteosarcoma. Targeting CSCs is a promising strategy to overcome chemoresistance and improve outcomes in osteosarcoma treatment. Besides the conventionally studied cytoplasmic p70 ribosomal protein S6...
Jingyu Zhou, Bo Li, Qi Gao et al.· Cellular Signalling· 0 citations
Cell fate is governed by signaling pathways involving diverse protein modifications. However, how protein AMPylation mediates signal transduction in mammalian cells remains largely unexplored. We demonstrate that the protein adenylyltransferase, SELENOO (SelO), is induced by chemotherapy, and has clinical relevance in...
Li Wu, Jie Wu, Wen-Qiang Xie et al.· Proceedings of the National...· 0 citations
Functional studies reveal that YTHDC1 facilitates MM cell growth and survival in an m6A-dependent manner and highlight the YTHDC1-EP300 axis as a promising target for therapeutic intervention.
Yi-Fan Hou, Qi-Qi Shen, J. Qu et al.· Oncogene· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.